Carboxypeptidase M

A biomarker for the discrimination of well-differentiated liposarcoma from lipoma

Michele R. Erickson-Johnson, Amber R. Seys, Christopher W. Roth, Allison A. King, Rachael L. Hulshizer, Xiaoke Wang, Yan Asmann, Ricardo V. Lloyd, Eapen K. Jacob, Andre M. Oliveira

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The discrimination between well-differentiated liposarcomas/atypical lipomatous tumors and lipomas can be diagnostically challenging at the histological level. However, cytogenetic identification of ring and giant rod chromosomes supports the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumor. These abnormal chromosomes are mainly composed of amplified genomic sequences derived from chromosome 12q13-15, and contain several genes, including MDM2, CDK4 (SAS), TSPAN31, HMGA2, and others. MDM2 is consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors, and up to 25% in other sarcomas. As part of a large genomic study of lipomatous neoplasms, we initially found CPM to be consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors. To further explore this initial finding, we investigated the copy number status of MDM2 and CPM by fluorescent in situ hybridization (FISH) on a series of 138 tumors and 17 normal tissues, including 32 well-differentiated liposarcoma/atypical lipomatous tumors, 63 lipomas, 11 pleomorphic lipomas, 2 lipoblastomas, 30 other tumors and 17 normal fat samples. All 32 well-differentiated liposarcoma/atypical lipomatous tumors showed amplification of MDM2 and CPM, usually 20 copies per cell. The other tumors lacked MDM2 and/or CPM amplification. Chromogenic in situ hybridization confirmed the above results on a subset of these tumors (n27). These findings suggest that identification of CPM amplification could be used as an alternative diagnostic tool for the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumors.

Original languageEnglish (US)
Pages (from-to)1541-1547
Number of pages7
JournalModern Pathology
Volume22
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Liposarcoma
Lipoma
Biomarkers
Neoplasms
carboxypeptidase M
Lipoblastoma
Chromosomes
Chromosomes, Human, Pair 15
Fluorescence In Situ Hybridization
Cytogenetics
Sarcoma
In Situ Hybridization

Keywords

  • CPM
  • FISH
  • Lipoma
  • MDM2
  • Well-differentiated liposarcoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Erickson-Johnson, M. R., Seys, A. R., Roth, C. W., King, A. A., Hulshizer, R. L., Wang, X., ... Oliveira, A. M. (2009). Carboxypeptidase M: A biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Modern Pathology, 22(12), 1541-1547. https://doi.org/10.1038/modpathol.2009.149

Carboxypeptidase M : A biomarker for the discrimination of well-differentiated liposarcoma from lipoma. / Erickson-Johnson, Michele R.; Seys, Amber R.; Roth, Christopher W.; King, Allison A.; Hulshizer, Rachael L.; Wang, Xiaoke; Asmann, Yan; Lloyd, Ricardo V.; Jacob, Eapen K.; Oliveira, Andre M.

In: Modern Pathology, Vol. 22, No. 12, 12.2009, p. 1541-1547.

Research output: Contribution to journalArticle

Erickson-Johnson, MR, Seys, AR, Roth, CW, King, AA, Hulshizer, RL, Wang, X, Asmann, Y, Lloyd, RV, Jacob, EK & Oliveira, AM 2009, 'Carboxypeptidase M: A biomarker for the discrimination of well-differentiated liposarcoma from lipoma', Modern Pathology, vol. 22, no. 12, pp. 1541-1547. https://doi.org/10.1038/modpathol.2009.149
Erickson-Johnson MR, Seys AR, Roth CW, King AA, Hulshizer RL, Wang X et al. Carboxypeptidase M: A biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Modern Pathology. 2009 Dec;22(12):1541-1547. https://doi.org/10.1038/modpathol.2009.149
Erickson-Johnson, Michele R. ; Seys, Amber R. ; Roth, Christopher W. ; King, Allison A. ; Hulshizer, Rachael L. ; Wang, Xiaoke ; Asmann, Yan ; Lloyd, Ricardo V. ; Jacob, Eapen K. ; Oliveira, Andre M. / Carboxypeptidase M : A biomarker for the discrimination of well-differentiated liposarcoma from lipoma. In: Modern Pathology. 2009 ; Vol. 22, No. 12. pp. 1541-1547.
@article{8d4ede5d6c284de8a19d04dbefcdd4a4,
title = "Carboxypeptidase M: A biomarker for the discrimination of well-differentiated liposarcoma from lipoma",
abstract = "The discrimination between well-differentiated liposarcomas/atypical lipomatous tumors and lipomas can be diagnostically challenging at the histological level. However, cytogenetic identification of ring and giant rod chromosomes supports the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumor. These abnormal chromosomes are mainly composed of amplified genomic sequences derived from chromosome 12q13-15, and contain several genes, including MDM2, CDK4 (SAS), TSPAN31, HMGA2, and others. MDM2 is consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors, and up to 25{\%} in other sarcomas. As part of a large genomic study of lipomatous neoplasms, we initially found CPM to be consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors. To further explore this initial finding, we investigated the copy number status of MDM2 and CPM by fluorescent in situ hybridization (FISH) on a series of 138 tumors and 17 normal tissues, including 32 well-differentiated liposarcoma/atypical lipomatous tumors, 63 lipomas, 11 pleomorphic lipomas, 2 lipoblastomas, 30 other tumors and 17 normal fat samples. All 32 well-differentiated liposarcoma/atypical lipomatous tumors showed amplification of MDM2 and CPM, usually 20 copies per cell. The other tumors lacked MDM2 and/or CPM amplification. Chromogenic in situ hybridization confirmed the above results on a subset of these tumors (n27). These findings suggest that identification of CPM amplification could be used as an alternative diagnostic tool for the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumors.",
keywords = "CPM, FISH, Lipoma, MDM2, Well-differentiated liposarcoma",
author = "Erickson-Johnson, {Michele R.} and Seys, {Amber R.} and Roth, {Christopher W.} and King, {Allison A.} and Hulshizer, {Rachael L.} and Xiaoke Wang and Yan Asmann and Lloyd, {Ricardo V.} and Jacob, {Eapen K.} and Oliveira, {Andre M.}",
year = "2009",
month = "12",
doi = "10.1038/modpathol.2009.149",
language = "English (US)",
volume = "22",
pages = "1541--1547",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Carboxypeptidase M

T2 - A biomarker for the discrimination of well-differentiated liposarcoma from lipoma

AU - Erickson-Johnson, Michele R.

AU - Seys, Amber R.

AU - Roth, Christopher W.

AU - King, Allison A.

AU - Hulshizer, Rachael L.

AU - Wang, Xiaoke

AU - Asmann, Yan

AU - Lloyd, Ricardo V.

AU - Jacob, Eapen K.

AU - Oliveira, Andre M.

PY - 2009/12

Y1 - 2009/12

N2 - The discrimination between well-differentiated liposarcomas/atypical lipomatous tumors and lipomas can be diagnostically challenging at the histological level. However, cytogenetic identification of ring and giant rod chromosomes supports the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumor. These abnormal chromosomes are mainly composed of amplified genomic sequences derived from chromosome 12q13-15, and contain several genes, including MDM2, CDK4 (SAS), TSPAN31, HMGA2, and others. MDM2 is consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors, and up to 25% in other sarcomas. As part of a large genomic study of lipomatous neoplasms, we initially found CPM to be consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors. To further explore this initial finding, we investigated the copy number status of MDM2 and CPM by fluorescent in situ hybridization (FISH) on a series of 138 tumors and 17 normal tissues, including 32 well-differentiated liposarcoma/atypical lipomatous tumors, 63 lipomas, 11 pleomorphic lipomas, 2 lipoblastomas, 30 other tumors and 17 normal fat samples. All 32 well-differentiated liposarcoma/atypical lipomatous tumors showed amplification of MDM2 and CPM, usually 20 copies per cell. The other tumors lacked MDM2 and/or CPM amplification. Chromogenic in situ hybridization confirmed the above results on a subset of these tumors (n27). These findings suggest that identification of CPM amplification could be used as an alternative diagnostic tool for the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumors.

AB - The discrimination between well-differentiated liposarcomas/atypical lipomatous tumors and lipomas can be diagnostically challenging at the histological level. However, cytogenetic identification of ring and giant rod chromosomes supports the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumor. These abnormal chromosomes are mainly composed of amplified genomic sequences derived from chromosome 12q13-15, and contain several genes, including MDM2, CDK4 (SAS), TSPAN31, HMGA2, and others. MDM2 is consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors, and up to 25% in other sarcomas. As part of a large genomic study of lipomatous neoplasms, we initially found CPM to be consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors. To further explore this initial finding, we investigated the copy number status of MDM2 and CPM by fluorescent in situ hybridization (FISH) on a series of 138 tumors and 17 normal tissues, including 32 well-differentiated liposarcoma/atypical lipomatous tumors, 63 lipomas, 11 pleomorphic lipomas, 2 lipoblastomas, 30 other tumors and 17 normal fat samples. All 32 well-differentiated liposarcoma/atypical lipomatous tumors showed amplification of MDM2 and CPM, usually 20 copies per cell. The other tumors lacked MDM2 and/or CPM amplification. Chromogenic in situ hybridization confirmed the above results on a subset of these tumors (n27). These findings suggest that identification of CPM amplification could be used as an alternative diagnostic tool for the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumors.

KW - CPM

KW - FISH

KW - Lipoma

KW - MDM2

KW - Well-differentiated liposarcoma

UR - http://www.scopus.com/inward/record.url?scp=71149096889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71149096889&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2009.149

DO - 10.1038/modpathol.2009.149

M3 - Article

VL - 22

SP - 1541

EP - 1547

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 12

ER -